Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 43 of the 75 sources its claims cite were checked for support.
Abstract
Protein phosphatase 2A (PP2A) is a critical human tumor suppressor. Cancerous inhibitor of PP2A (CIP2A) supports the activity of several critical cancer drivers (Akt, MYC, E2F1) and promotes malignancy in most cancer types via PP2A inhibition. However, the 3D structure of CIP2A has not been solved, and it remains enigmatic how it interacts with PP2A. Here, we show by yeast two-hybrid assays, and subsequent validation experiments, that CIP2A forms homodimers. The homodimerization of CIP2A is confirmed by solving the crystal structure of an N-terminal CIP2A fragment (amino acids 1-560) at 3.0 Å resolution, and by subsequent structure-based mutational analyses of the dimerization interface. We further describe that the CIP2A dimer interacts with the PP2A subunits B56α and B56γ. CIP2A binds to the B56 proteins via a conserved N-terminal region, and dimerization promotes B56 binding. Intriguingly, inhibition of either CIP2A dimerization or B56α/γ expression destabilizes CIP2A, indicating opportunities for controlled degradation. These results provide the first structure-function analysis of the interaction of CIP2A with PP2A/B56 and have direct implications for its targeting in cancer therapy.
Overview
CoChat Summary
## TL;DR
This study reports the first crystal structure of CIP2A and shows that CIP2A forms homodimers via a C-terminal three-helix dimerization interface. It also shows that CIP2A directly binds the PP2A B56a and B56c subunits, and that this binding is promoted by dimerization and contributes to CIP2A protein stability.
## Key findings
- Yeast two-hybrid screening with full-length CIP2A as bait identified CIP2A itself as a high-confidence interaction partner; selected interaction domain analysis mapped the homodimerization region to amino acids 388–558, with the crystallized fragment CIP2A(1–560) behaving as a dimer.
- The CIP2A(1–560) crystal structure was solved at 3.0 Å resolution; SEC-MALS gave a molecular mass of 117.2 kDa for CIP2A(1–560), consistent with a dimer (calculated 124.5 kDa).
- Mutations in the dimer interface reduced dimerization: L533E inhibited dimerization by up to 70%, and R522D caused about 50% inhibition; both mutations also reduced B56a binding.
- CIP2A directly interacted with PP2A B56 subunits B56a and B56c, with the minimal N-terminal B56-binding region mapped to amino acids 159–245; one mutant, N230E, significantly inhibited B56a binding.
- Disrupting CIP2A dimerization or depleting B56a/B56c lowered full-length CIP2A protein levels by up to 50% in HEK293T cells, without changing CIP2A mRNA; the L533E effect was also validated in 22RV1 cells and was associated with reduced pAkt Ser473.
## Methods
- Structural and biochemical study of CIP2A: yeast two-hybrid screening, GST pull-downs, SEC and SEC-MALS, microscale thermophoresis, proximity ligation assay, crystallography, and structure-guided mutagenesis.
- Sample/cell systems: recombinant human CIP2A(1–560) expressed in E. coli for structural and binding assays; HEK293T, HeLa, and 22RV1 cells for interaction and protein-stability experiments; endogenous CIP2A dimerization assessed in HeLa extracts.
- Main analyses: crystal structure determination by SeMet SAD at 3.0 Å; quantitative comparison of wild-type vs mutant dimerization and B56 binding; Western blot and RT-qPCR to test effects on protein and mRNA abundance.
## Limitations
- The authors state that co-crystallization of the CIP2A–B56a complex was “extremely challenging” and remained an ongoing effort, so the exact molecular basis of the interaction was not resolved.
- They note that although N-terminal and dimerization regions were sufficient for B56 binding, the C-terminal sequences and post-translational modifications of full-length CIP2A might also contribute; this is a limitation of the fragment-based structural work.
- Evident from the text: the N-terminal half of CIP2A(1–560) had high B factors and was not fully traceable in the structure, so parts of the model are incomplete.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 2 Not valid · 6 Not checked · 55 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“the patients with both of these alterations constituted the patient population with clearly the worst outcome [13]”
What the sources say
- Supportedcites [13] Kauko O, Laajala TD, Jumppanen M, Hintsanen P, Suni V, Haapaniemi P, Corthals G, Aittokallio T, Westermarck J, Imanishi SY (2015) Label‐free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling. Sci Rep 5: 13099 source
The Results section reports that high CIP2A expression combined with high KRAS expression was associated with the worst survival in TCGA pan-cancer data. It adds that activating KRAS mutations showed a similar synergistic relationship with CIP2A expression, supporting the claim for patients with both alterations. The mutation analysis was based on a limited number of patients. (LLM, conf=0.86)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“high CIP2A protein expression predicts poor patient survival in over a dozen different cancer types [20]”
What the sources say
- Partly supportedcites [20] Khanna A, Pimanda JE (2015) Clinical significance of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancers. Int J Cancer 138: 525–532 sourceExperimental — accuracy not yet measured
The Prognostic Role section says CIP2A expression has an established prognostic role in over 10 tumor types and reports associations with poorer survival in several cancers. It does not establish the claim’s more specific count of over a dozen types with poor survival predicted by high CIP2A protein expression; the section also notes conflicting prognostic findings. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“PP2A complex components are mutated at a relatively low frequency in most types of human cancer”
What the sources say
- Partly supportedcites [2] Perrotti D, Neviani P (2013) Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 14: e229–e238 sourceExperimental — accuracy not yet measured
Section 3, “PP2A in disease and cancer” (page unavailable), reports PR65β mutations in 13–15% of several primary cancers and PR65α alterations in 6.7–19.2% of several tumor categories. These figures support relatively low frequencies in the examples given, but the passage does not establish that PP2A complex components generally are mutated at low frequency in most types of human cancer; it also reports PR65α alterations in 43% of primary gliomas. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [6] Khanna A, Pimanda JE, Westermarck J (2013) Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res 73: 6548–6553 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CIP2A overexpression is required for RAS-driven human cell transformation [10]”
What the sources say
- Partly supportedcites [10] Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala‐aho R, Nielsen C, Ivaska J, Taya Y et al (2007) CIP2A inhibits PP2A in human malignancies. Cell 130: 51–62 sourceExperimental — accuracy not yet measured
The Discussion reports that CIP2A expression transforms human HEK-TERV cells immortalized by Ras, TERT, and large-T antigen. This supports a role for CIP2A in that transformation model, but it does not establish that CIP2A overexpression is required for RAS-driven human cell transformation generally. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“we recently demonstrated significant overlap between CIP2A and RAS-regulated phosphoproteomes [13]”
What the sources say
- Supportedcites [13] Kauko O, Laajala TD, Jumppanen M, Hintsanen P, Suni V, Haapaniemi P, Corthals G, Aittokallio T, Westermarck J, Imanishi SY (2015) Label‐free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling. Sci Rep 5: 13099 source
The Discussion (page not provided) says the integrated results revealed extensive overlap between the CIP2A- and RAS-regulated phosphoproteomes. The Abstract also reports significant overlap in their functional pathways. (LLM, conf=0.92)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
51 more claims · 9 with their cited sources checked
Create a free account to see all 90 claims and every source verdict.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 12
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alternatively, selective B subunit inhibition has also been characterized through the overexpression of endogenous PP2A inhibitors such as the Cancerous Inhibitor of PP2A (CIP2A) which selectively sequesters B56 family subunits to prevent B56 specific PP2A holoenzyme activity (Junttila et al., 2007; Wang et al., 2017).”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Wang et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, similar to CIP2A, NOCIVA retains the capability to dimerize and bind to B56a, indicating that it functions similarly to CIP2A as a PP2A inhibitor protein (1).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The only thus far available structure of CIP2A spans the first 560 amino acids of the protein and reveals that CIP2A is an obligate homodimer interacting with B56 proteins31.”
From Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A (2023) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Cancerous inhibitor of protein phosphatase 2A (CIP2A) functions as an oncoprotein by directly binding to the tumor suppressor PP2A-B56a (1,2).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“According to this model, CIP2A traps B56 proteins (B56 a and B56 g and possibly other B56 subunits as well).”
From Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis (2019) · cites this paper as Wang et al., 2017
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ CIP 2 A homodimerization
“The SID analysis for interaction between two CIP2A molecules indicated that CIP2A homodimerization is mediated by a region encompassing amino acids 388 -558 (Figs 1A and EV1C).”
§ Figure 1 . Verification of homodimerization of the CIP 2 A( 1 -560 ).
“These results reveal that CIP2A homodimerizes, and suggest that the dimerization is mediated by a region containing amino acids 338 -558.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mutational analysis of CIP 2 A( 1 -560 ) dimerization interface
“Notably, the mode of interference in dimerization by these mutants was reflected with their potency on reducing pulled-down parental CIP2A(1 -560)-V5 protein; L533E inhibited dimerization by up to 70%, whereas R552D being not directly involved in interaction surface caused ~ 50% inhibition (Fig 3D and E).”
§ Generation of CIP 2 A N 230 E, R 522 D, and L 533 E mutants
“R522D and L533E mutations were introduced by PCR, using QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, TX, USA).”
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Protein production by auto-induction in high-density shaking cultures
Studier, F. W. (2005) · Protein Expression and Purification · doi:10.1016/j.pep.2005.01.016 · Cited by 5,931
Rules for Making Human Tumor Cells
Hahn, W. C., & Weinberg, R. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra021902 · Cited by 951
Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 3×
“Impact of CIP2A on both oncogenic RAS signaling [10,13,36] and MYC activity in vivo [10,12,22], without lack of any detrimental normal tissue homeostasis effects in a CIP2A-deficient mouse model [11,22,23], further illustrated the potential of CIP2A as a future cancer therapy target.”
Self-citationProtein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Structure of the Protein Phosphatase 2A Holoenzyme
Xu, Y., Xing, Y., Chen, Y., Chao, Y., Lin, Z., Fan, E., Yu, J. W., Strack, S., Jeffrey, P. D., & Shi, Y. (2006) · Cell · doi:10.1016/j.cell.2006.11.033 · Cited by 450 · cited 1×
“We also assumed that the binding on CIP2A may occur at positively charged areas, since B56 surface is largely negatively charged [34,35].”
Cited by
Elgendy, M., Cirò, M., Hosseini, A., Weiszmann, J., Mazzarella, L., Ferrari, E., Cazzoli, R., Curigliano, G., DeCensi, A., Bonanni, B., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.007 · Cited by 299
“A recent study resolved the 3D structure of CIP2A (Wang et al., 2017) and showed that CIP2A forms homodimers, which interact with the PP2A B56 subunits leading to CIP2A stabilization.”
BackgroundMicropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression
Guo, B., Wu, S., Zhu, X., Zhang, L., Deng, J., Li, F., Wang, Y., Zhang, S., Wu, R., Lu, J., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019102190 · Cited by 243
“…report has shown that PP2A’s subunits B56 c and B56 a also bind to the N-terminus of CIP2A (amino acid 159 – 245) to maintain the stability of CIP2A dimer (Wang et al , 2017; Wu et al , 2017), we hypothesized that CIP2A-BP and these two subunits might compete for the same CIP2A binding site.”
Selective PP2A enhancement through biased heterotrimer stabilization
Leonard, D., Huang, W., Izadmehr, S., O’Connor, C. M., Wiredja, D. D., Wang, Z., Zaware, N., Chen, Y., Schlatzer, D. M., Kiselar, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.038 · Cited by 176
“…selective B subunit inhibition has also been characterized through the overexpression of endogenous PP2A inhibitors such as the cancerous inhibitor of PP2A (CIP2A) that selectively sequestersB56 family subunits topreventB56-specificPP2Aholoenzyme activity (Junttila et al., 2007; Wang et al., 2017).”
BackgroundSelf-citationMission Possible: Advances in MYC Therapeutic Targeting in Cancer
Allen-Petersen, B. L., & Sears, R. C. (2019) · BioDrugs · doi:10.1007/s40259-019-00370-5 · Cited by 148
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
Self-citationFang, D., Ou, X., Sun, K., Zhou, X., Li, Y., Shi, P., Zhao, Z., He, Y., Peng, J., & Xu, J. (2022) · Cancer Science · doi:10.1111/cas.15581 · Cited by 133
Physiologic functions of PP2A: Lessons from genetically modified mice
Reynhout, S., & Janssens, V. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.07.010 · Cited by 124
Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer
Kauko, O., & Westermarck, J. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.005 · Cited by 111
Self-citationAdam, S., Rossi, S. E., Moatti, N., De Marco Zompit, M., Xue, Y., Ng, T. F., Álvarez-Quilón, A., Desjardins, J., Bhaskaran, V., Martino, G., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00266-w · Cited by 121
Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration
Clark, A. R., & Ohlmeyer, M. H. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.016 · Cited by 122
Vainonen, J. P., Momeny, M., & Westermarck, J. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe2967 · Cited by 104
Self-citationPP2A-B′ holoenzyme substrate recognition, regulation and role in cytokinesis
Wu, C.-G., Chen, H., Guo, F., Yadav, V. K., Mcilwain, S. J., Rowse, M., Choudhary, A., Lin, Z., Li, Y., Gu, T., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.27 · Cited by 85
CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease
Shentu, Y.-P., Huo, Y., Feng, X.-L., Gilbert, J., Zhang, Q., Liuyang, Z.-Y., Wang, X.-L., Wang, G., Zhou, H., Wang, X.-C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.009 · Cited by 90
“Third, the first crystal structure of CIP2A was recently published and revealed potential druggable structures (Wang et al., 2017).”
BackgroundSelf-citationPredictomes, a classifier-curated database of AlphaFold-modeled protein-protein interactions
Schmid, E. W., & Walter, J. C. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.01.034 · Cited by 120
PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.009 · Cited by 93
Kauko, O., Imanishi, S. Y., Kulesskiy, E., Yetukuri, L., Laajala, T. D., Sharma, M., Pavic, K., Aakula, A., Rupp, C., Jumppanen, M., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011265 · Cited by 65
“S1I) may be at least partly due to the direct inhibition of the catalytic activity of PP2Ac by SET (27, 28) and the limited selectivity toward specific B-subunit– containing PP2A trimers, as is the case with PME-1 or CIP2A (10, 26, 39).”
BackgroundSelf-citationThe CIP2A-TOPBP1 complex safeguards chromosomal stability during mitosis
Zompit, M. D. M., Esteban, M. T., Mooser, C., Adam, S., Rossi, S. E., Jeanrenaud, A., Leimbacher, P.-A., Fink, D. A., Shorrocks, A.-M. K., Blackford, A. N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31865-5 · Cited by 76
Elgenaidi, I. S., & Spiers, P. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.011 · Cited by 73
Liu, S., Bu, X., Kan, A., Luo, L. Q., Yj, X., Chen, H., Lin, X. H., Lai, Z.-C., Wen, D., Huang, L., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.026 · Cited by 64
Westermarck, J. (2018) · The FEBS Journal · doi:10.1111/febs.14617 · Cited by 50
Self-citationLaine, A., Nagelli, S. G., Farrington, C., Butt, U., Cvrljevic, A. N., Vainonen, J. P., Feringa, F. M., Grönroos, T. J., Gautam, P., Khan, S., et al. (2020) · doi:10.1101/2020.08.27.269902 · Cited by 54
“SMAPs activate the CIP2A-regulated PP2A-B56alpha 466 heterotrimer (14,44), and the cellular effects of SMAPs in cancer cells are both correlated 467 with PP2A reactivation capacity, and can be rescued by concomitant PP2A inhibition 468 (22,45).”
Self-citationRaman, D., & Pervaiz, S. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101105 · Cited by 59
Liu, X., Sun, Z., Li, D., Deng, J., Liu, J., Ma, K.-H., Qin, S., Si, Y., Zhang, T., Feng, T., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4464 · Cited by 54
“CIP2A is a oncogene that may facilitate cell transformation and tumorigenesis via inhibiting PP2A activities, as it is a protein phosphatase that regulates several critical oncogenic signal proteins including Akt, c-Myc, ERK and p70S6K (38-40).”
CIP2A induces PKM2 tetramer formation and oxidative phosphorylation in non-small cell lung cancer
Liang, L.-J., Yang, F., Wang, D., Zhang, Y., Yu, H., Wang, Z., Sun, B., Liu, Y., Wang, G., & Zhou, G. (2024) · Cell Discovery · doi:10.1038/s41421-023-00633-0 · Cited by 54
Self-citationPP2A-B55: substrates and regulators in the control of cellular functions
Amin, P., Awal, S., Vigneron, S., Roque, S., Méchali, F., Labbé, J. C., Lorca, T., & Castro, A. (2021) · Oncogene · doi:10.1038/s41388-021-02068-x · Cited by 48
“The crystal structures of CIP2A, ANP32 and SET are shown.”
BackgroundNader, C. P., Cidem, A., Verrills, N. M., & Ammit, A. J. (2019) · Respiratory Research · doi:10.1186/s12931-019-1192-x · Cited by 42
Kim, M.-O., Choe, M. H., Yoon, Y. N., Ahn, J., Yoo, M., Jung, K., An, S., Hwang, S., Oh, J. S., & Kim, J. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.009 · Cited by 40
Altering phosphorylation in cancer through PP2A modifiers
Johnson, H., Narayan, S., & Sharma, A. K. (2024) · Cancer Cell International · doi:10.1186/s12935-023-03193-1 · Cited by 47
Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A
Pavic, K., Gupta, N., Omella, J. D., Derua, R., Aakula, A., Huhtaniemi, R., Määttä, J. A., Höfflin, N., Okkeri, J., Wang, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36693-9 · Cited by 36
“The data show that the CIP2A(1-560) residues cross-linked to B56α are located primarily in the N-terminal head domain (K18, K21, E23, E34, K40) with an additional residue at the C-terminus (K490) (Fig.”
BackgroundMethodInfluentialSelf-citationThe Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias
Pippa, R., & Odero, M. D. (2020) · Cells · doi:10.3390/cells9030544 · Cited by 41
Predictomes: A classifier-curated database of AlphaFold-modeled protein-protein interactions
(2024) · doi:10.1101/2024.04.09.588596 · Cited by 121
PPP2R5A: A multirole protein phosphatase subunit in regulating cancer development
Mao, Z., Liu, C., Lin, X., Sun, B., & Su, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.024 · Cited by 30
Regulation and role of the PP2A-B56 holoenzyme family in cancer
Peris, I., Romero-Murillo, S., Vicente, C., Narla, G., & Odero, M. D. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188953 · Cited by 30
PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen
Tinsley, S. L., & Allen-Petersen, B. L. (2022) · NAR Cancer · doi:10.1093/narcan/zcac002 · Cited by 26
“However, CIP2A has been identified to only interact with PP2A complexes that contain B56 family subunits (52).”
BackgroundWang, H., Choe, M. H., Lee, I., Namgoong, S., Kim, J., Kim, N., & Oh, J. S. (2017) · Development · doi:10.1242/dev.158584 · Cited by 29
“Because CIP2A has a coiledcoil domain in the C-terminal region (Wang et al., 2017), we asked whether the coiled-coil domain of CIP2A is required for centrosomal localization.”
BackgroundPP2A and Its Inhibitors in Helper T-Cell Differentiation and Autoimmunity
Khan, M. M., Ullah, U., Khan, M. H., & Lahesmaa, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786857 · Cited by 28
“This binding inhibits holoenzyme formation (41).”
BackgroundPosner, Z., Yannuzzi, I., & Prensner, J. R. (2023) · Protein Science · doi:10.1002/pro.4708 · Cited by 28
PP2A-B55 Holoenzyme Regulation and Cancer
Goguet-Rubio, P., Amin, P., Awal, S., Vigneron, S., Charrasse, S., Méchali, F., Labbé, J. C., Lorca, T., & Castro, A. (2020) · Biomolecules · doi:10.3390/biom10111586 · Cited by 25
CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response
Nagelli, S. G., & Westermarck, J. K. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.09.001 · Cited by 26
Self-citationChang, W.-H., Liu, Y., Hammes, E. A., Bryant, K. L., Cerione, R. A., & Antonyak, M. A. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102842 · Cited by 26
“pCDNA3 expression constructs encoding Myc-tagged Survivin (Sino Biological), HA-tagged MYC (Addgene #74164) (54), V5-tagged CIP2A (Addgene #119287) (55), GFP-tagged MYC (Addgene #42142) (56), and mCherry-LC3B (Addgene #40827) (57) were transfected into MEFs using PEI (Sigma) and PDAC cells using FuGENE 6 (Promega) per…”
MethodCIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling
Khan, M. M., Ullah, U., Khan, M. H., Kong, L., Moulder, R., Välikangas, T., Bhosale, S. D., Komsi, E., Rasool, O., Chen, Z. J., et al. (2020) · iScience · doi:10.1016/j.isci.2020.100947 · Cited by 21
Self-citationYin, J., Chen, D., Luo, K., Lu, M., Gu, Y., Zeng, S., Chen, X., Song, Y., Zhang, Z., Zheng, G., et al. (2019) · Journal of Cancer · doi:10.7150/jca.35704 · Cited by 23
“Cip2a has attracted attention because of its oncogenic potential and tumor-promoting role in several xenograft studies[21, 22, 23, 24, 25, 26].”
BackgroundNeale, D. B., Morris, J. C., Verrills, N. M., & Ammit, A. J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108834 · Cited by 27
Gonnella, R., Yadav, S., Montani, M. S. G., Granato, M., Santarelli, R., Garufi, A., D’Orazi, G., Faggioni, A., & Cirone, M. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.005 · Cited by 21
Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells
Manoharan, G. B., Okutachi, S., & Abankwa, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268635 · Cited by 18
“Deregulation of the PP2A tumor suppressor in cancer typically occurs by the upregulation of endogenous inhibitors, such as cancerous inhibitor of PP2A (CIP2A), which selectively sequesters B56 family B subunits [30, 31].”
BackgroundKhanna, A., Thoms, J. A. I., Stringer, B. W., Chung, S. A., Ensbey, K. S., Jue, T. R., Jahan, Z., Subramanian, S., Anande, G., Shen, H. M., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0934 · Cited by 22
“Interestingly, a recent study has demonstrated direct interaction with the regulatory PP2A subunits B56a/PPP2R5A andB56g/PPP2R5C (29).”
BackgroundTan, S., Donato, M. D., Glanc, M., Zhang, X., Klíma, P., Liu, J., Bailly, A., Ferro, N., Petrášek, J., Geisler, M. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108463 · Cited by 19
Mäkelä, E., Löyttyniemi, E., Salmenniemi, U., Kauko, O., Varila, T., Kairisto, V., Itälä‐Remes, M., & Westermarck, J. K. (2019) · Cancers · doi:10.3390/cancers11111774 · Cited by 21
“This can be rationalized as ARPP19 can control both directly its own PP2A/B55-subunit targets [33], but also PP2A/B56-subunit targets via CIP2A [21] (Figure 3c).”
BackgroundSelf-citationMäkelä, E., Pavic, K., Varila, T., Salmenniemi, U., Löyttyniemi, E., Nagelli, S. G., Ammunét, T., Kähäri, V.-M., Clark, R. E., Elo, L. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3679 · Cited by 18
Self-citationCazzoli, R., Romeo, F., Pallavicini, I., Peri, S., Romanenghi, M., Pérez-Valencia, J. A., Hagag, E., Ferrucci, F., Elgendy, M., Vittorio, O., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112616 · Cited by 18
Self-citationCIP2A is a prime synthetic-lethal target for BRCA-mutated cancersPreprint
Adam, S., Rossi, S. E., Moatti, N., Zompit, M. D. M., Ng, T. F., Álvarez-Quilón, A., Desjardins, J., Bhaskaran, V., Martino, G., Setiaputra, D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.08.430060 · Cited by 17
Protein Phosphatases—A Touchy Enemy in the Battle Against Glioblastomas: A Review
Tomiyama, A., Kobayashi, T., Mori, K., & Ichimura, K. (2019) · Cancers · doi:10.3390/cancers11020241 · Cited by 19
“and blocks the B56 regulatory subunits of PP2A complex [52], and importantly, high expression of”
BackgroundCell-permeable peptide-based delivery vehicles useful for subcellular targeting and beyond
Stillger, K., & Neundorf, I. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110796 · Cited by 15
Shentu, Y., Hu, W., Liang, J., Liuyang, Z., Wei, H., Qun, W., Wang, X., Wang, J., Westermarck, J. K., & Liu, R. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190830113420 · Cited by 16
Self-citationBrink, H. J., van Senten, J. R., Leeuwen, I. J. D. V.-V., Pereira, D. D. C., Piersma, S. R., Jiménez, C. R., Centorrino, F., Ottmann, C., Siderius, M. H., Smit, M. J., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00299 · Cited by 15
Tarek, M., Yahia, A., Elnakib, M., & ElHefnawi, M. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104986 · Cited by 16
van Pelt, J. F., Meeusen, B., Derua, R., Guffens, L., Cutsem, E. V., Janssens, V., & Verslype, C. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04145-z · Cited by 11
Yin, S., Chen, Y., Tong, H., Li, T., Qin, Z., Zhu, J., & He, W. (2022) · Oncology Letters · doi:10.3892/ol.2022.13221 · Cited by 11
“Previous studies revealed that a PP2A agonist increased the levels of apoptosis by downregulating cellular inhibitor of PP2A expression levels (48,49).”
BackgroundThe CIP2A-TOPBP1 complex safeguards chromosomal stability during mitosisPreprint
Zompit, M. D. M., Mooser, C., Adam, S., Rossi, S. E., Jeanrenaud, A., Leimbacher, P.-A., Fink, D. A., Durocher, D., & Stucki, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.08.430274 · Cited by 12
Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells
Hayashi, T., Hikichi, M., Yukitake, J., Wakatsuki, T., Nishio, E., Utsumi, T., & Harada, N. (2018) · Oncotarget · doi:10.18632/oncotarget.25217 · Cited by 12
“The stability of CIP2A is influenced by PP2A [43].”
BackgroundRules for PP2A-controlled phosphosignalling and drug responsesPreprint
Kauko, O., Imanishi, S. Y., Kulesskiy, E., Laajala, T. D., Yetukuri, L., Laine, A., Jumppanen, M., Haapaniemi, P., Ruan, L., Yadav, B., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/271841 · Cited by 11
Self-citationClark, R. E., Basabrain, A. A., Austin, G. M., Holcroft, A. K., Loaiza, S., Apperley, J. F., Law, C., Scott, L. J., Parry, A. D., Bonnett, L. J., et al. (2021) · Cancers · doi:10.3390/cancers13092155 · Cited by 13
“The minimum region required for CIP2A binding to β56α and β56γ has been identified as residues 159–245 [36]; however, a structure containing both CIP2A and PP2A components has yet to be identified.”
BackgroundTinsley, S. L., Chianis, E. R. D., Shelley, R. A., Mall, G. K., Dhiman, A., Baral, G., Kothandaraman, H., Thoma, M. C., English, I. A., Daniel, C. J., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03196-w · Cited by 11
Emerging Roles of B56 Phosphorylation and Binding Motif in PP2A-B56 Holoenzyme Biological Function
Zhang, Y., Jiang, H., Yin, H., Zhao, X., & Zhang, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063185 · Cited by 11
“It is suggested that CIP2A binds to PP2A-B56 (B56 α and B56 γ ) through its N-terminus resulting in the expulsion of A-subunit and forming a disguised heterotrimer CIP2A-B56 α -PP2Ac, thereby stabilizing CIP2A and promoting its tumorigenicity [30,31].”
BackgroundProtein Phosphatase 2a Inhibits Gastric Cancer Cell Glycolysis by Reducing MYC Signaling
Zhang, W., Cai, Z., Zhou, R., Liu, X., Feng, Y., & Feng, Y. (2022) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-022-01112-1 · Cited by 9
“Moreover, CIP2A is overexpressed in gastric cancer and predicts a poor prognosis; CIP2A knockdown is shown to negatively affect clonogenicity and senescence of tumor cells [29, 30, 31].”
BackgroundMonga, J., Suthar, S. K., Rohila, D., Joseph, A., Chauhan, C., & Sharma, M. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154116 · Cited by 10
de Haan, L., Dijt, S. J., García-López, A., Ruan, D., Martzios, P., Bakker, F. J., Everts, M., Warner, H. M., Mol, F. N., Chapman, J. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66549-3 · Cited by 11
Thapa, C. J., Roivas, P., Haataja, T., Permi, P., & Pentikäinen, U. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.650881 · Cited by 8
Protein interactome of the Cancerous Inhibitor of protein phosphatase 2A (CIP2A) in Th17 cells
Khan, M. M., Välikangas, T., Khan, M. H., Moulder, R., Ullah, U., Bhosale, S. D., Komsi, E., Butt, U., Qiao, X., Westermarck, J. K., et al. (2020) · Current Research in Immunology · doi:10.1016/j.crimmu.2020.02.001 · Cited by 10
“Interestingly, inhibition of 84 either CIP2A dimerization or B56a/g expression destabilizes CIP2A in cancer cells 85 [13] .”
InfluentialSelf-citationTargeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
“…demethyl-ating L309 and thereby inactivating PP2A [93, 94] ∎ CIP2A interacts with B56α and B56γ, preventing their assembly into the holoenzyme [95, 96] ∎ α-endosulfine interacts with B55δ, impeding its activity [97] Viral Infections ∎ Small t-antigen of simian virus 40 (SV40) interacts with…”
Emerging roles of the CIP2A–TopBP1 complex in genome integrity
Ummethum, H., Li, J., Lisby, M., & Oestergaard, V. H. (2023) · NAR Cancer · doi:10.1093/narcan/zcad052 · Cited by 8
“CIP2A is known to dimerize and is speculated to oligomer-ize via its coiled-coil domain ( 27 ,28 ) .”
BackgroundXu, F., Li, J., Ai, M., Zhang, T., Ming, Y., Li, C., Pu, W., Yang, Y., Li, Z., Qi, Y., et al. (2024) · MedComm · doi:10.1002/mco2.758 · Cited by 7
“20 This mechanism involves CIP2A binding to the B56 subunit of PP2A through its conserved N-terminal region, promoting CIP2A homodimerization and blocking PP2A-A subunit binding.”
BackgroundMomeny, M., Arsiola, T., & Westermarck, J. K. (2021) · Biochemical Journal · doi:10.1042/bcj20210254 · Cited by 6
Self-citationLiu, Z., Xi, Q., Hou, M., Zou, T., Liu, H., Zhou, X., Jin, L., Zhu, L., & Zhang, X. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167228 · Cited by 5
Broken chromosomes heading into mitosis: More than one way to patch a flat tire
Messer, C. L., & Fox, D. T. (2024) · The Journal of Cell Biology · doi:10.1083/jcb.202401085 · Cited by 5
“CIP2A, as its name implies, is best known for inhibiting the cell cycle regulatory Phosphatase PP2A and is activated through dimerization (Wang et al., 2017).”
BackgroundExploring CIP2A modulators using multiple molecular modeling approaches
Bhowmick, S., Roy, K., & Saha, A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1821781 · Cited by 7
“No such variations in contact potentials have been measured (± 0.6) for chains A and B. Earlier, it has been reported that amino acid residues extending from 507 to 559 appeared to be responsible for CIP2A dimerization (Wang et al., 2017).”
BackgroundMethodInfluentialAustin, J. A., Jenkins, R. E., Austin, G. M., Glenn, M. A., Dunn, K. M., Scott, L. J., Lucas, C., & Clark, R. E. (2019) · Biochemical Journal · doi:10.1042/bcj20190121 · Cited by 7
de Haan, L., Dijt, S. J., López, A. G., Ruan, D., Bakker, F. J., Everts, M., Warner, H. M., Mol, F. N., de Boer, H. R., Veld, P. J. H. I. ’., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.03.647079 · Cited by 4
Ibitoye, O. E., Ibrahim, M. A. A., & Soliman, M. E. S. (2023) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2023.2298903 · Cited by 5
“…B56 c regulatory subunits eliminates the responsibility of PP2A to carry out enzyme-catalyzed chemical reactions, catabolism, and anabolism of cellular pathways, preservation of genetic material, DNA transfer, and maintenance of cellular signal transduction, thereby promoting tumorigenesis [4,10].”
BackgroundMethodInfluentialStrategies for in Silico Drug Discovery to Modulate Macromolecular Interactions Altered by Mutations
Poudel, P., Miteva, M. A., & Alexov, E. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl26339 · Cited by 3
Li, L., Fu, Q., Shao, J., Wang, B., Ding, Z., Yuan, S. S., Peng, J., Xin, W., Zhu, J., & Chen, Y. (2022) · Cell and Tissue Research · doi:10.1007/s00441-022-03619-8 · Cited by 5
“1 3 Endogenous CIP2A, which interacts with PP2A, is directly associated with c-Myc; it inhibits the role of PP2A in inducing the expression c-Myc S62, thereby stabilizing the structure of c-Myc protein (Wang et al. 2017).”
BackgroundDang, X., Lin, H., Yayi, Y., Yang, B., Juancong, D., Zhang, Z., Yang, K. C., Li, Y., Li, X., Chai, D., et al. (2021) · Dose-Response · doi:10.1177/15593258211056190 · Cited by 4
Nishio, E., Hayashi, T., Akaza, M. D. H., Hisatomi, Y., Hikichi, M., Fujii, T., Utsumi, T., Harada, N., & Shimono, Y. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.12956 · Cited by 3
CIP2A expression predicts recurrences of tamoxifen-treated breast cancer
Baldacchino, S., Wastall, L. M., Saliba, C., Hughes, T. A., Scerri, C. A., Berwick, A., Speirs, V., Hanby, A. M., & Grech, G. (2017) · Tumor Biology · doi:10.1177/1010428317722064 · Cited by 5
The PP2A pathway plays a crucial role in controlling cardiac physiology
Cristóbal, I., Santos, A., Rojo, F., & García‐Foncillas, J. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00203.2022 · Cited by 2
Rivard, R. S., Morris, J. M., & Youngman, M. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229812 · Cited by 2
Day, A., Huang, W., Léonard, D., O’Connor, C. M., Narla, G., & Taylor, D. J. (2025) · Structure · doi:10.1016/j.str.2025.06.013 · Cited by 2
Szudy‐Szczyrek, A., Mlak, R., Mazurek, M., Krajka, T., Chocholska, S., Bitkowska, P., Jutrzenka, M., Szczyrek, M., Homa‐Mlak, I., Krajka, A., et al. (2023) · Cells · doi:10.3390/cells12071029 · Cited by 1
“[35] revealed that, with its N-terminal (amino acids 1–560), CIP2A could bind directly to the B56α and B56γ subunits of the PP2A protein—both of which are tumor suppressor units—and that the region necessary for this was located between the amino acids 159 and 245 and positively charged.”
BackgroundDiscovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemiasPreprint
Mäkelä, E., Pavic, K., Varila, T., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.24.264606 · Cited by 1
Self-citationRivard, R. S., Morris, J. M., & Youngman, M. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.18.953687 · Cited by 1
Zhao, X., Chen, B., Xu, F., Zhang, J., Yao, Z., Wang, R., Zhang, J., Zhou, S., Hou, Y., Xu, S., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2600248123 · Cited by 2
The Emerging Role of the Cancerous Inhibitor of Protein Phosphatase 2A in Pulmonary Diseases
Hamza, H., Nirmal, D., Pappas, S., Ebubechukwu, U. J., Gill, S., Al-Ajam, A., Ohlmeyer, M. H. J., & Geraghty, P. M. (2025) · Medicina · doi:10.3390/medicina61101740
“Signaling that alters CIP2A dimerization decreases CIP2A protein stability and function [37].”
InfluentialRibaudo, G., Pagano, M. A., Anyanwu, M., Giannangeli, M., Vezzoli, M., Visentin, A., Frezzato, F., Trentin, L., Brunati, A. M., & Gianoncelli, A. (2025) · Macromol—A Journal of Macromolecular Research · doi:10.3390/macromol5030043 · Cited by 1
Aging-dependent dysregulation of EXOSC2 is maintained in cancer as a dependencyPreprint
Skamagki, M., Zhang, C., Hacisuleyman, E., Galleti, G., Wu, C., Rajasekhar, V. K., Cha, H., Ata, D., Kim, J., Weisskittel, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.04.647279
Tinsley, S. L., Shelley, R. A., Mall, G. K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.01.547283
Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cellsPreprint
Okutachi, S., Manoharan, G. B., & Abankwa, D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.16.448716
Clinical Research Progress of Cancer Axis CIP2A
李, 琳. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.119583
Yu, E. W. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737780632.793574081
Protein Interactome of the Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Th17 CellsPreprint
Khan, M. M., Välikangas, T., Khan, M. H., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/809459
Self-citation
Metadata
- Authors
- Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., & Westermarck, J.
- Affiliations
- University of Washington (US)
- Åbo Akademi University (FI)
- University of Helsinki (FI)
- Nankai University (CN)
- Corresponding author
- Xu, Wenqing
- Westermarck, Jukka
- ORCID
- Venue
- The EMBO Reports
- Published
- 2017-02-07
- Volume
- 18
- Issue
- 3
- Pages
- 437-450
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- PMC
- PMC5331240
- OpenAlex
- W2586089906
- Cited by
- 95
- References
- 47
- Citations by year
- 2026: 1 · 2025: 10 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 15 · 2020: 12 · 2019: 13 · 2018: 8 · 2017: 6
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- EMBO Reports (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Academy of Finland (138963)
- Cancer Society of Finland
- Sigrid Juselius Foundation
- Emil Aaltonen Foundation
- National Cancer Institute (R21CA201944)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CIP2A, protein phosphatase 2A, PP2A-B56, protein dimerization, protein-protein interaction, protein stability, protein degradation, tumor suppressor, crystal structure, structure-function analysis, cancer therapy targets
- MeSH terms
- Autoantigens, Binding Sites, Humans, Membrane Proteins, Models, Molecular, Mutation, Protein Binding, Protein Conformation, Structure-Activity Relationship, Oncogene Proteins, Protein Subunits, Tumor Suppressor Proteins, Protein Interaction Mapping, Intracellular Signaling Peptides and Proteins, Protein Phosphatase 2, Protein Multimerization, Protein Stability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.